Therapeutic Response
HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Nivolumab in combination with Oxaliplatin in patients with Esophagogastric Adenocarcinoma.
Statements
| Source and description |
|---|
HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Nivolumab in combination with Oxaliplatin in patients with Esophagogastric Adenocarcinoma.
| Source and description |
|---|